Daratumumab delays progression in smoldering multiple myeloma

Smoldering multiple myeloma (SMM) is an asymptomatic premalignant precursor of active multiple myeloma (MM). Results of the presented phase III AQUILA study show that daratumumab significantly delays the progression of SMM to active multiple myeloma (MM) in high-risk patients.